Menu Search
Equities

Avid Bioservices Inc

TEHP:BER

Avid Bioservices Inc

Actions
  • Price (EUR)11.40
  • Today's Change-0.10 / -0.87%
  • Shares traded--
  • 1 Year change+143.59%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024 07:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization (CDMO) focused on development and Current Good Manufacturing Practices (CGMP) manufacturing of biologics. The Company provides a comprehensive range of process development, CGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. Its services include CGMP clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing and regulatory submissions support. For early-stage programs the Company provides a variety of process development activities, including cell line development, upstream and downstream development and optimization, analytical methods development, testing and characterization. The scope of its services ranges from standalone process development projects to full development and manufacturing programs through commercialization. Commercial biologics produced by it are distributed to over 90 countries.

  • Revenue in USD (TTM)142.36m
  • Net income in USD-144.17m
  • Incorporated1996
  • Employees371.00
  • Location
    Avid Bioservices Inc14191 MYFORD ROADTUSTIN 92780United StatesUSA
  • Phone+1 (714) 508-6100
  • Fax+1 (714) 838-5817
  • Websitehttps://avidbio.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.